THE WOODLANDS, Texas--(EON: Enhanced Online News)--On the heels of its recent announcement of six key members of its U.S. executive team, MolecularHealth has now signed the first three members of its advisory board. The board members, who bring decades of combined experience in pathology and oncology, will advise the company as it moves towards the commercialization of its automated genetic diagnostic platform for cancer care in the first quarter of 2014.
“MolecularHealth’s offering is exciting not only because of its advanced analytic capabilities, but because of the attention being paid to factors that interfere with a treatment’s ability to work, impacting toxicity and efficacy.”
Joyce O'Shaughnessy, M.D., is a nationally recognized expert on breast cancer prevention and treatment, Co-Chair of Breast Cancer Research at US Oncology and a member of US Oncology's Scientific Advisory Board. Dr. O'Shaughnessy received her medical degree from Yale Medical School and is board certified in both internal medicine and medical oncology. She completed a fellowship in medical oncology at the National Cancer Institute, where she later served as a senior investigator.
“We’re in the beginning stages of a revolution in medicine that is changing how we diagnose and treat disease. Cancer is a prime target for understanding the role of the genome in diagnosis and personalized care,” said Dr. O'Shaughnessy. “I’m very pleased to be part of the MolecularHealth team as we work to develop a new and innovative approach to improving personalized treatment options for cancer patients and their families.”
Burton M. Schwartz, M.D., F.A.C.P., is a founding member of Minnesota Oncology, the largest oncology practice in Minnesota, and a long-time board member of US Oncology. Dr. Schwartz received his medical degree from Meharry Medical College in Nashville, Tenn. and is triple board certified in internal medicine, medical oncology and hematology.
“We are now at a point in the oncology field where we can treat certain types of cancer on a patient-by-patient basis, looking at tumors at the molecular level,” said Dr. Schwartz. “MolecularHealth’s offering is exciting not only because of its advanced analytic capabilities, but because of the attention being paid to factors that interfere with a treatment’s ability to work, impacting toxicity and efficacy.”
Thomas M. Wheeler, M.D., serves as Chairman of the Department of Pathology and Immunology at Baylor College of Medicine in Houston, where he also completed medical school and residency. Dr. Wheeler is a board certified pathologist who specializes in prostate cancer.
“As a pathologist, I am the ultimate broker of the tissue diagnosis that leads to specific patient treatments by the oncologist,” said Dr. Wheeler. “The pathologist is the critical link between the raw molecular data and the clinical oncologist, and the tools that MolecularHealth provides enables the pathologist to function in this role in the most efficient manner.”
Lloyd Everson, M.D., CEO of MolecularHealth, added, “As we work toward bringing MolecularHealth’s platform to market in 2014, it’s crucial that we have a board of extremely high-level experts in oncology and pathology to complement our scientific and clinical development team. Drs. Wheeler, O'Shaughnessy and Schwartz all bring unique academic and research backgrounds, and see patients with a broad range of oncology challenges. I speak for the whole executive team when I say that we look forward to working with them as we shape our offering.”
After eight years of development by a multidisciplinary team of doctors, scientists and IT experts in Heidelberg, Germany, MolecularHealth is preparing for the commercial launch of its genetic diagnostic platform. The company, backed by Dietmar Hopp, co-founder and former chairman and CEO of SAP, offers an end-to-end service that walks patients and their healthcare providers through the molecular diagnostic process—collecting tumor samples, analyzing the samples, and interpreting the results using a unique analytics platform—all to generate safer and more targeted cancer treatment choices. As part of its offering, MolecularHealth will provide patients, oncologists and pathologists with complete logistical support and help navigating insurance reimbursement for recommended treatments.
MolecularHealth delivers on the promise of personalized, precision medicine. By using advanced proprietary information technologies to sift through terabytes of genetic and molecular test findings in a fraction of the time needed for current manual analysis, MolecularHealth provides doctors and patients with faster, more accurate insights into the role genes play in the progression and treatment of an individual’s cancer. Eight years in development by a multidisciplinary team of doctors, scientists and IT experts, MolecularHealth works in partnership with some of the world’s leading healthcare and information technology companies, including the University of Texas MD Anderson Cancer Center, SAP AG, and the U.S. Food and Drug Administration (FDA). The company has headquarters in The Woodlands, Texas; Basel, Switzerland; and Heidelberg, Germany. Visit www.molecularhealth.com for more information.